Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ofev
Synonyms :
nintedanib
Class :
Tyrosine Kinase Inhibitors, Pulmonary
Brand Name :
Ofev
Synonyms :
nintedanib
Class :
Tyrosine Kinase Inhibitors, Pulmonary
Dosage Forms & StrengthsÂ
capsuleÂ
150mgÂ
100mgÂ
Idiopathic Pulmonary FibrosisÂ
150
mg
Orally 
twice a day
Interstitial Lung Diseases with a Chronic Fibrosing Progressive Phenotype
150 mg orally 2 times a day
Interstitial Lung Disease with associated Systemic Sclerosis
150 mg orally 2 times a day
Dose Adjustments
Dosage Modifications
Dose adjustments as a result of adverse reactions
the adverse reactions may need a dosage reduction or just a temporary interruption till the specificed adverse reaction get resolves.
Resume at 150 mg every 12 hours, or 100 mg every 12 hours, which can then be increased to the maximum dose (150 mg q12hr)
If 100 mg every 12 hours is not tolerated, the medication should be discontinued.
liver enzymes Elevated
AST/ALT levels more than 3 to 5 times the ULN without the signs for severe liver damage: Reduce or discontinue medication to 100 mg BID; after LFTs returns to normal, can reintroduce at 100 mg twice a day, which can be later increased to 150 mg twice a day.
AST/ALT levels more than 5times ULN or greater than 3times ULN with signs and symptoms for severe liver damage: Discontinue
Renal impairment
Mild and moderate: dosage adjustment is not necessary
ESRD or Severe (CrCl less than 30 mL/min): Not recommended Hepatic impairment
Mild (Child Pugh score A): 100 mg orally every 12hours
Moderate and severe (Child Pugh score B or C): usually Not recommended
Safety and efficacy were not establishedÂ
Refer to the adult dosing regimenÂ
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
CYP3A strong enhancers of the small intestine may reduce the bioavailability of nintedanib 
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may have an increasingly adverse effect when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with nintedanib
Letrozole may enhance the serum concentration of nintedanib
Anastrozole may enhance the serum concentration of nintedanib
may enhance the serum concentration when combined with nintedanib
Actions and spectrum:Â
Nintedanib is a selective kinase inhibitor with antineoplastic properties targeting receptors involved in angiogenesis, fibrosis, and tumorigenesis. It suppresses cancer cell growth, reduces inflammation and tissue scarring in diseases like idiopathic pulmonary fibrosis.Â
Frequency definedÂ
<1%Â
Idiopathic pulmonary fibrosisÂ
1-10%Â
SSc-ILDÂ
Idiopathic pulmonary fibrosisÂ
>10%Â
SSc-ILDÂ
Idiopathic pulmonary fibrosisÂ
Post marketing ReportsÂ
ThrombocytopeniaÂ
RashÂ
AlopeciaÂ
PancreatitisÂ
Drug-induced liver injuryÂ
PruritusÂ
Nephrotic range proteinuriaÂ
Black Box Warning:Â
Fatal liver injury.Â
Contraindication/Caution:Â
It is contraindicated for patients with known hypersensitivity to the drug and those with idiopathic pulmonary fibrosis with liver impairment or end-stage renal disease.Â
Pregnancy consideration: US FDA pregnancy category: Not assignedÂ
Lactation: It is not known whether nintedanib is excreted in human milk.Â
Â
Pregnancy category:Â
Pharmacology:Â
Nintedanib targets fibroblast growth factor, vascular endothelial growth factor and platelet-derived growth factor receptors inhibiting intracellular signaling pathways by reducing angiogenesis and fibrosis.Â
Pharmacodynamics:Â
Nintedanib is a tyrosine kinase inhibitor that selectively inhibits intracellular tyrosine kinases slowing disease progression by inhibiting angiogenesis and fibrogenesis.Â
Pharmacokinetics:Â
AbsorptionÂ
It is rapidly absorbed.Â
DistributionÂ
It is highly bound to plasma proteins and volume of distribution is approximately 16.1 L.Â
MetabolismÂ
Metabolized in the liver by CYP3A4 and CYP3A5 enzymes.Â
Elimination and excretionÂ
Eliminated by feces 92%.Â
Administration:Â
It should be taken orally with doses adjusted for severe impairments.Â
Patient information leafletÂ
Generic Name: nintedanibÂ
Pronounced: (nin-TEH-da-nib)Â
Why do we use nintedanib?Â
Nintedanib treats idiopathic pulmonary fibrosis, interstitial lung diseases, advanced NSCLC, and other conditions.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
